Research collaboration secured with Mayo Clinic
Filed with ASX · · 2 pages · English
Summary by 6ix AI
EchoIQ Limited has announced a research collaboration with Mayo Clinic to evaluate its AI platform for cardiac risk stratification in cancer patients receiving therapy. The study aims to assess the ability of Echo IQ's AI technology to generate predictive risk scores for heart failure using echocardiographic data. This collaboration targets the growing cardio-oncology sector, focusing on managing cardiovascular complications associated with cancer treatment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from EchoIQ
- $762k R&D Tax Incentive Received
- Echo IQ Announces EchoSolv AS Deployed into Mount Sinai Health System
- QuarterlyActivities Report and Appendix 4C Cash Flow Report
- EchoSolv AS deployed into Mount Sinai Health System
- Agreement with Mayo Clinic for EchoSolv HF
Later from EchoIQ
- EchoIQ Strengthens Leadership Team and Clinical Advisory Network to Accelerate Next Phase of Commercial Growth and U.S. FDA Initiatives
- Binding HOA secured with Pro Medicus Limited
- Echo IQ Raises A$110m via Institutional Placement
- Exclusive Imaging Dataset Strengthens AI Competitive Moat
- Quarterly Activities Report & Appendix 4C Cashflow Report
Follow EchoIQ into a list and get an email when it puts out news.
Follow EchoIQ